Refractory Neuroblastoma clinical trials

Explore recruiting refractory neuroblastoma clinical trials.

Recruiting refractory neuroblastoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Refractory Neuroblastoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

BEACON: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma

Belgium, Spain, Netherlands, France, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

J1O-MC-JZHD: A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTA0-Tyr3-Octreotate in Children with Refractory or Recurrent Neuroblastoma expressing somatostatin receptors

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

A phase I/II trial of ABTL0812 in children with relapsed/refractory neuroblastoma and other solid tumours

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A phase I/II trial of ABTL0812 in children with relapsed/refractory neuroblastoma and other solid tumours

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A5481092: PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS

Sweden, France, Czechia, Slovakia, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Refractory Neuroblastoma trials by city

Refractory Neuroblastoma in Toronto Refractory Neuroblastoma in Vancouver Refractory Neuroblastoma in Montreal Refractory Neuroblastoma in Calgary Refractory Neuroblastoma in Edmonton Refractory Neuroblastoma in Ottawa Refractory Neuroblastoma in Winnipeg Refractory Neuroblastoma in Quebec City Refractory Neuroblastoma in Hamilton Refractory Neuroblastoma in Kitchener Refractory Neuroblastoma in London Refractory Neuroblastoma in Halifax Refractory Neuroblastoma in New York Refractory Neuroblastoma in Los Angeles Refractory Neuroblastoma in Chicago Refractory Neuroblastoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease